Physician profile
Eric Myers
NPI 1598016099
$3,135.74
in general payments reported to CMS, 2019-2025
14 companies · $729 in 2025
The $729 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.35 · 2022: $211 · 2023: $1,749 · 2024: $374 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183 · Honoraria: $1,000 · Travel and Lodging: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.40 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $668.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $1,345.28 | 2023-2025 | Sotalol Hydrochloride |
| Abiomed | $982.60 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $209.69 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $198.50 | 2022-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $129.67 | 2023-2025 | Onpattro |
| Pfizer INC. | $53.05 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $42.25 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $33.61 | 2023 | Camzyos |
| Cvrx, INC. | $29.03 | 2023 | Barostim Neo System |
| Philips North America LLC | $21.01 | 2023 | |
| Merck Sharp & Dohme LLC | $13.51 | 2021 | |
| Abbott Laboratories | $13.00 | 2022 | |
| Amarin Pharma, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.